Trial reportIranian journal of medical sciences2026
Ursodeoxycholic Acid in the Management of Prolonged Neonatal Hyperbilirubinemia: A Randomized Controlled Clinical Trial.
Trial report in Iranian journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prolonged indirect hyperbilirubinemia (PIH) is defined as bilirubin levels >10 mg/dL for more than 14 days in term infants and 21 days in preterm infants. Although the role of ursodeoxycholic acid (UDCA) as an adjunct to phototherapy has been evaluated, evidence in PIH remains limited. Therefore, this study aimed to investigate the effects of UDCA on PIH. Methods: This randomized controlled trial was conducted on infants with PIH in Rasht, Iran, (July 2023-July 2024). Participants were enrolled through consecutive sampling and randomly assigned to intervention or control groups. The intervention group received 10 mg/Kg/day UDCA for 5 days. The control group received no intervention and was observed. Bilirubin, ABO, and Rh blood group status were measured on day 1 and day 5. Data were analyzed using an independent samples Results: Fifty-eight patients were included, with 29 in each group. Both groups showed a significant reduction in bilirubin levels over 5 days (control: 12.26±1.65 to 10.09±2.74 mg/dL; intervention: 11.96±1.48 to 9.07±3.45 mg/dL; P<0.001). The mean bilirubin reduction was 2.17±2.50 mg/dL in the control group and 2.89±3.00 mg/dL in the intervention group, with no statistically significant difference between groups (P=0.323). On day 5, bilirubin levels were 10.09±2.74 mg/dL in the control group and 9.07±3.45 mg/dL in the intervention group (P=0.216). ABO incompatibility was associated with lower bilirubin levels on day 5 in the intervention group (7.26±2.33 vs. 9.76±3.61 mg/dL; P=0.041). Rh incompatibility was correlated with greater bilirubin reduction over 5 days (4.98±1.54 vs. 2.45±3.07 mg/dL; P=0.025). Conclusion: Five-day UDCA therapy did not significantly reduce bilirubin levels in infants with PIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.